Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 1-12471 THE ARENA GROUP HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41898 IRON HORSE ACQUISITIONS CORP. (Exact name of registrant as specified in its charter) | Delaware | 87-4105289 | | --- | --- | | (State or other jurisdiction of | (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41898 IRON HORSE ACQUISITIONS CORP. (Exact name of registrant as specified in its charter) | Delaware | 87-4105289 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | ...

EXHIBIT 99.1 Oblong Reports Q2 2025 Results and Expands $8M TAO Treasury to Power Decentralized AI 21,613 TAO Tokens Now Staked to Generate Revenue and Strengthen Oblong's Role in Bittensor's AI Ecosystem August 14, 2025 – (BUSINESS WIRE) – Oblong, Inc. (Nasdaq: OBLG) ("Oblong" or the "Company"), a digital asset treasury company, today announced financial results for the second quarter ended June 30, 2025 ("Q2 2025") and significant progress in its treasury strategy centered on Bittensor's TAO token. With a ...

Exhibit 99.1 Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, August 14, 2025 – Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended Jun ...

Exhibit 99.1 Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Operating loss in the second quarter of 2025 was $6.6 million, compared to $4.4 million in the second quarter of 2024. On a non- GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating los ...

Exhibit 99.1 Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update LOS ALTOS, California, August 14, 2025 -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update. "Our team has made great progress in the second quarter and we have request ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 001-41905 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR Delaware 52-2214851 (State or other jurisdiction of incorporation or organization) 117 Kendrick St, Suite 450 Needham, MA 02494 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (617) 916-54 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40925 Xilio Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...